EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis

Helena Marzo-Ortega, Stephanie R Harrison, George E Fragoulis, Xabier Michelena, Cristina Macía-Villa, Sibel Z Aydin, Andra Balanescu, Heidi Bertheussen, Christine Bundy, Maria Sole Chimenti, Paolo Gisondi, Bente Glintborg und 15 weitere

Annals of the Rheumatic Diseases · 2026-01 · 85 (1) · 61-74

DOI: 10.1016/j.ard.2025.10.002 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of the Rheumatic Diseases, 2026-01. Verfasst von Helena Marzo-Ortega und 26 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, Universi…. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EULAR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to develop evidence-based points to consider (PtC) and consensus definitions of difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA). METHODS: A multidisciplinary international European Alliance of Associations for Rheumatology (EULAR) task force (TF) of 27 members, including rheumatologists, dermatologists, health practitioners, and patient partners, was established, and the EULAR standardised operating procedures, including a systematic literature review and a consensus process, were followed. RESULTS: The TF formulated 4 overarching principles addressing the proportion of patients with PsA with an unsatisfactory treatment response despite the best standard of care, and for which the causes are likely multifactorial. Six PtC highlight criterion relevant for subsequent definitions including failure to achieve or maintain response to ≥2 biological/targeted synthetic disease-modifying antirheumatic drugs with ≥2 different mechanisms of action; management of signs and symptoms perceived as problematic by the rheumatologist and/or the patient, and evidence of persistent disease activity in the presence of extramusculoskeletal manifestations and/or comorbidities and/or objective evidence of inflammatory activity. Finally, the following 2 definitions were developed: (1) D2M PsA, an umbrella term including drivers such as inflammation, comorbidities, psychosocial or other factors, incorporating (2) TR PsA, defined by persistent disease activity and objective evidence of active inflammation. CONCLUSIONS: EULAR proposes 2 consensus definitions to identify a D2M PsA population, including a TR subgroup. These definitions should now be tested in research studies to understand disease pathogenesis and improve care for people living with PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, PsoriaticHumansAdvisory CommitteesRheumatology

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Electronic address: h.marzo-ortega@leeds.ac.uk.
  • NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Institute of Cardiovascular and Metaboli…
  • Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Athens, Greece.
  • Rheumatology Unit, Digitalization for the Sustainability of the Healthcare System (DS3) and Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Rheumatology Department, Ramón y Cajal University Hospital, Madrid, Spain.
  • Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Förderung

  • EULAR

Zitieren

APA

Marzo-Ortega, H., Harrison, S. R., Fragoulis, G. E., Michelena, X., Macía-Villa, C., Aydin, S. Z., Balanescu, A., Bertheussen, H., Bundy, C., Chimenti, M. S., Gisondi, P., Glintborg, B., Gossec, L., Kalyoncu, U., Lubrano, E., Nagy, G., Wagenaar, W., Puig, L., Queiro, R., …, & Siebert, S. (2026). EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Annals of the Rheumatic Diseases, 85(1), 61-74. https://doi.org/10.1016/j.ard.2025.10.002

Vancouver

Marzo-Ortega H, Harrison SR, Fragoulis GE, Michelena X, Macía-Villa C, Aydin SZ, et al. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Annals of the Rheumatic Diseases. 2026;85(1):61-74. doi:10.1016/j.ard.2025.10.002

BibTeX
@article{MarzoOrtega2026,
  author = {Marzo-Ortega, Helena and Harrison, Stephanie R and Fragoulis, George E and Michelena, Xabier and Macía-Villa, Cristina and Aydin, Sibel Z and Balanescu, Andra and Bertheussen, Heidi and Bundy, Christine and Chimenti, Maria Sole and Gisondi, Paolo and Glintborg, Bente and Gossec, Laure and Kalyoncu, Umut and Lubrano, Ennio and Nagy, Gyorgy and Wagenaar, Wendy and Puig, Luis and Queiro, Rubén and Rahman, Proton and Shumnalieva, Russka and Soriano, Enrique R and van den Bosch, Filip and van de Sande, Marleen M G H and Sepriano, Alexandre and Machado, Pedro M and Siebert, Stefan},
  title = {EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {1},
  pages = {61--74},
  doi = {10.1016/j.ard.2025.10.002}
}
Kostenlos starten →